<DOC>
	<DOCNO>NCT01674530</DOCNO>
	<brief_summary>The objective study evaluate clinical equivalence safety test formulation Lubiprostone 24 mcg capsule manufacture Dr Reddy 's Laboratories Ltd compare market formulation AMITIZA® ( Lubiprostone ) 24 mcg capsule ( Sucampo Pharmaceuticals , Inc. ) patient confirm Chronic Idiopathic Constipation</brief_summary>
	<brief_title>Evaluation Clinical Equivalence Between Two Lubiprostone Products Treatment Chronic Idiopathic Constipation</brief_title>
	<detailed_description>Constipation common gastrointestinal problem estimate effect 2-27 % population United States . It find commonly woman elderly . The prevelance constipation grow demand treatment dictate need safe effective treatment option . Lubiprostone first chloride channel activator approve FDA long term treatment chronic idiopathic constipation adult men woman . To provide generic medicine U.S population Dr Reddy 's Laboratories intend conduct study evaluate Lubiprostone manufacture equally effective safe market AMITIZA® ( Lubiprostone ) 24 mcg capsule ( Sucampo Pharmaceuticals , Inc . )</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Lubiprostone</mesh_term>
	<criteria>Main 1 . Patients sign write informed consent form prior enter study . 2 . Male nonpregnant female age ≥ 18 year clinical diagnosis CIC define , average , &lt; 3 SBMs per week confirm daily diary two week baseline/washout period . An SBM define bowel movement ( BM ) occur within 24 hour rescue medication use . 3 . Patients body mass index 18 35kg/m2 ( inclusive ) 4 . Have one follow symptom related BMs least 6 month baseline visit confirm daily diary 2 week baseline/washout period : i. hard ( little ball ) and/or hard stool least 25 % bowel movement ii . sensation incomplete evacuation follow least 25 % bowel movement iii . strain defecation least quarter time 5 . Women childbearing potential negative serum pregnancy test prior begin therapy agree use effective contraceptive method ( least one medically approve highly effective method birth control define result low failure rate ( i.e. , less 1 % per year ) use consistently correctly implant , injectables , oral contraceptive combine least one barrier method , hormonal IUDs , sexual abstinence vasectomy partner ) study . 6 . For patient age &lt; 50 year , documentation result either flexible sigmoidoscopy colonoscopy perform within five year prior dose , show mechanical bowel obstruction organic disorder large small bowel . 7 . For patient age ≥ 50 year , documentation result either barium enema flexible sigmoidoscopy colonoscopy perform within one year prior dosing , show mechanical bowel obstruction organic disorder large small bowel . Main 1 . Females pregnant , breast feeding , plan pregnancy propose study period . 2 . Patients age evidence weight loss , anemia , rectal bleeding without documentation result either flexible sigmoidoscopy colonoscopy perform 6 month prior dose . 3 . Patients document mechanical bowel obstruction ( e.g. , bowel obstruction due tumor , hernia ) , megacolon/megarectum , diagnosis pseudoobstruction . 4 . Patients know suspected organic disorder large small bowel ( e.g. , inflammatory bowel disease , ulcerative colitis , Crohn 's Disease ) constipation secondary document cause ( e.g. , surgery , bowel resection ) acute hernia neurologic diseases disease cause motility problem example Parkinson 's disease spinal cord injury , etc . 5 . Patients history bowel resection . 6 . Patients regularly use medication , know cause constipation ( anticholinergic , narcotic , calcium channel blocker , tricyclic antidepressant , colchicine , iron supplement , magnesium supplement ) . 7 . Patients hospitalize gastrointestinal abdominal surgical procedure three month prior dose . 8 . Patients clinically significant cardiovascular , liver , lung , neurologic , renal psychiatric disorder , clinically significant laboratory abnormality ( laboratory value exceed 2X Upper Limit Normal approval medical monitor take consideration randomize patient ) . 9 . Use systemic antibiotic within four week prior baseline . 10 . Any current planned significant change diet study . 11 . Participation study investigational medication within past 30 day screen study previous participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>